Overexpression of hepatocyte growth factor in SBMA model mice has an additive effect on combination therapy with castration

Biochem Biophys Res Commun. 2015 Dec 25;468(4):677-83. doi: 10.1016/j.bbrc.2015.11.015. Epub 2015 Nov 7.

Abstract

Spinal and bulbar muscular atrophy (SBMA) is an inherited motor neuron disease caused by the expansion of a polyglutamine (polyQ)-encoding tract within the androgen receptor (AR) gene. The pathologic features of SBMA are motor neuron loss in the spinal cord and brainstem and diffuse nuclear accumulation and nuclear inclusions of mutant AR in residual motor neurons and certain visceral organs. Hepatocyte growth factor (HGF) is a polypeptide growth factor which has neuroprotective properties. To investigate whether HGF overexpression can affect disease progression in a mouse model of SBMA, we crossed SBMA transgenic model mice expressing an AR gene with an expanded CAG repeat with mice overexpressing HGF. Here, we report that high expression of HGF induces Akt phosphorylation and modestly ameliorated motor symptoms in an SBMA transgenic mouse model treated with or without castration. These findings suggest that HGF overexpression can provide a potential therapeutic avenue as a combination therapy with disease-modifying therapies in SBMA.

Keywords: Akt; Androgen receptor; Castration; Combination therapy; Hepatocyte growth factor; Spinal and bulbar muscular atrophy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Castration / methods*
  • Combined Modality Therapy / methods
  • Disease Models, Animal*
  • Hepatocyte Growth Factor / metabolism*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Muscular Disorders, Atrophic / metabolism*
  • Muscular Disorders, Atrophic / therapy*
  • Treatment Outcome
  • Up-Regulation

Substances

  • HGF protein, mouse
  • Hepatocyte Growth Factor